MBX Biosciences (MBX) Institutional Ownership

During the previous two years, 41 institutional investors and hedge funds held shares of MBX Biosciences. The most heavily invested institutionals were Frazier Life Sciences Management L.P. ($155.50M), NEA Management Company LLC ($93.90M), Wellington Management Group LLP ($52.99M), RA Capital Management L.P. ($39.26M), Driehaus Capital Management LLC ($29.15M), Price T Rowe Associates Inc. MD ($21.41M), and Woodline Partners LP ($11.22M).Learn more on MBX's institutional investors.

Of the 38 institutional investors that purchased MBX Biosciences stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Frazier Life Sciences Management L.P. ($5.99M), NEA Management Company LLC ($3.61M), Wellington Management Group LLP ($2.94M), RA Capital Management L.P. ($1.51M), Driehaus Capital Management LLC ($600.44K), Franklin Resources Inc. ($450K), and Geode Capital Management LLC ($265.70K).

Institutional investors have bought a total of 16,401,541 shares in the last 24 months. This purchase volume represents approximately $413.90M in transactions.

The following institutional investors have sold MBX Biosciences stock in the last 24 months: Millennium Management LLC ($106.77K), Franklin Resources Inc. ($80.70K), Alyeska Investment Group L.P. ($50.30K), Price T Rowe Associates Inc. MD ($31.41K), and Wellington Management Group LLP ($28.21K).

Institutional investors have sold a total of 297,394 shares in the last 24 months. This volume of shares sold represents approximately $5.48M in transactions.